TrialJournal of neurology2022

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.

Ralf Gold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.